A HISTORY OF GLOBAL SOLUTIONS
The Jean Boulle Group acquires promising assets and projects and optimizes their structure, management and development with private and public investment.
NEWS AND MEDIA
Luxembourg, 22 February 2021
The Jean Boulle Group (“the Group”) is pleased to confirm the appointment of Jean-Raymond Boulle to the Board of the Corporate Council on Africa (“CCA”). [...]
Jean Boulle Medtech company VDYNE obtains significant investment from a large global medical device company to close $21 million financing for human trials of ground breaking transfemoral tricuspid heart valve replacement technology
Jean Boulle Medtech Ltd is pleased to announce that VDYNE, Inc. ("VDYNE" or “the Company”), a privately held medical device company founded by Jean Boulle Medtech to develop a transcatheter replacement tricuspid valve, has closed a $21 million, heavily subscribed Series C financing. [...]
Trained Therapeutix Discovery Inc. Appoints Dr. Willem Mulder as Chief Scientific Officer - Expert in Use of Nanomaterials as Immunotherapeutics, Former Professor at Icahn School of Medicine at Mount Sinai, and Professor at Eindhoven University of Technology and Radboud University Medical Center
5 January, 2021
Trained Therapeutix Discovery, Inc. (“TTxD”), an immunotherapy biotech company founded by Jean Boulle Therapeutics, announces the appointment of Prof. Dr. Willem Mulder as Chief Scientific Officer effective 1 January 2021. [...]
Copyright © 2019 Jean Boulle Group. All rights reserved.